Angiogenesis in Ischemic and Neoplastic Disorders

Annual Review of Medicine

Volumn 54, Issue , 2003, Pages 17-28

  Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiopoietin; Coronary collateral; Hypoxia inducible factor 1; Infarction; Vascular endothelial growth factor

Indexed keywords

2 (8 HYDROXY 6 METHOXY 1 OXO 1H 2 BENZOPYRAN 3 YL)PROPIONIC ACID; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; ABT 518; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANGIOZYME; BEVACIZUMAB; CILENGITIDE; COMBRETASTATIN A4; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; HYPOXIA INDUCIBLE FACTOR 1; IM 862; INTERLEUKIN 12; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PI 88; PRINOMASTAT; REBIMASTAT; S 3304; SQUALAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VATALANIB; DNA BINDING PROTEIN; ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LYMPHOKINE; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; CANCER THERAPY; ENDOTHELIUM CELL; GENE ACTIVATION; HYPOXEMIA; ISCHEMIA; ISCHEMIC HEART DISEASE; MOUSE; NEOPLASM; NONHUMAN; OXYGEN TRANSPORT; PRIORITY JOURNAL; REVIEW; ANIMAL; CELL HYPOXIA; COLLATERAL CIRCULATION; GENE EXPRESSION; GENETICS; HEART MUSCLE ISCHEMIA; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; CELL HYPOXIA; COLLATERAL CIRCULATION; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MYOCARDIAL ISCHEMIA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037872699     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.54.101601.152418     Document Type: Review

References (67)

1. Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature 407: 249-57
2. Risau W, Flamme I. 1995. Vasculogenesis. Annu. Rev. Cell Dev. Biol. 11:73-91
3. Folkman J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1:27-31
4. Ware JA, Simons M. 1997. Angiogenesis in ischemic heart disease. Nat. Med. 3:158-64
5. Isner JM, Kalka C, Kawamoto A, et al. 2001. Bone marrow as a source of endothelial cells for natural and iatrogenic vascular repair. Ann. NY Acad. Sci. 953:75-84
6. Luttun A, Carmeliet G, Carmeliet P. 2002. Vascular progenitors: from biology to treatment. Trends Cardiovasc. Med. 12:88-96
7. Gale NW, Yancopoulos GD. 1999. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev. 13:1055-66
8. Yancopoulos GD, Davis S, Gale NW, et al. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407:242-48
9. Carmeliet P, Ferreira V, Breier G, et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-39
10. Ferrara N, Carver-Moore K, Chen H, et al. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-42
11. Suri C, McClain J, Thurston G, et al. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-80
12. Maisonpierre PC, Suri C, Jones PF, et al. 1997. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60
13. Lindahl P, Johansson BR, Leveen P, et al. 1997. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-45
14. Dickson MC, Martin JS, Cousins FM, et al. 1995. Defective hematopoiesis and vasculogenesis in transforming growth factor-β1 knockout mice. Development 121:1845-54
15. Tomanek RJ, Zheng W, Peters KG, et al. 2001. Multiple growth factors regulate coronary embryonic vasculogenesis. Dev. Dyn. 221:265-73
16. LeCouter J, Kowalski J, Foster J, et al. 2001. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412:877-84
17. Stevens T, Rosenberg R, Aird W, et al. 2001. NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am. J. Physiol. Cell Physiol. 281:C1422-C33
18. Carmeliet P, Moons L, Luttun A, et al. 2001. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7:575-83
19. Libby P, Schonbeck U. 2001. Drilling for oxygen: Angiogenesis involves proteolysis of the extracellular membrane. Circ. Res. 89:195-97
20. Banai S, Shweiki D, Pinson A, et al. 1994. Upregulation of vascular endothelial growth factor expression induced by myocardial ischemia: implications for coronary angiogenesis. Cardiovasc. Res. 28:1176-79
21. White FC, Carroll SM, Magnet A, et al. 1992. Coronary collateral development in swine after coronary artery occlusion. Circ. Res. 71:1490-500
22. Sabia PJ, Powers ER, Ragosta M, et al. 1992. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N. Engl. J. Med. 321:1825-31
23. Semenza GL. 2001. Regulation of hypoxia-induced angiogenesis: A chaperone escorts VEGF to the dance. J. Clin. Invest. 108:39-40
24. Semenza GL. 2000. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J. Clin. Invest. 106:809-12
25. Lee SH, Wolf PL, Escudero R, et al. 2000. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N. Engl. J. Med. 342:626-33
26. 2 tension. Proc. Natl. Acad. Sci. USA 92:5510-14
27. Bruick RK, McKnight SL. 2001. A conserved family of prolyl-4- hydroxylases that modify HIF. Science 294:1337-40
28. Epstein AC, Gleadle JM, McNeill LA, et al. 2001. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43-54
29. 2 sensing. Science 292:464-68
30. 2 regulated prolyl hydroxylation. Science 292:468-72
31. Martin C, Yu AY, Jiang BH, et al. 1998. Cardiac hypertrophy in chronically anemic fetal sheep: Increased vascularization is associated with increased myocardial expression of vascular endothelial growth factor and hypoxia-inducible factor 1. Am. J. Obstet. Gynecol. 178:527-34
32. Rivard A, Fabre JE, Silver M, et al. 1999. Age-dependent impairment of angiogenesis. Circulation 99:111-20
33. Frenkel-Denkberg G, Gershon D, Levy AP. 1999. The function of hypoxia-inducible factor 1 (HIF-1) is impaired in senescent mice. FEBS Lett. 462:341-44
34. Rivard A, Berthou-Soulie L, Principe N, et al. 2000. Age-dependent defect in vascular endothelial growth factor expression is associated with reduced hypoxia-inducible factor 1 activity. J. Biol. Chem. 275:29643-47
35. Schultz A, Lavie L, Hochberg I, et al. 1999. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 100:547-52
36. Isner JM. 2002. Myocardial gene therapy. Nature 415:234-39
37. Epstein SE, Fuchs S, Zhou YF, et al. 2001. Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results, and potential hazards. Cardiovasc. Res. 49:532-42
38. Blau HM, Banfi A. 2001. The well-tempered vessel. Nat. Med. 7:532-33
39. Thurston G, Suri C, Smith K, et al. 1999. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511-14
40. Dvorak HF, Nagy JA, Feng D, et al. 1999. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237:1-30
41. Elson DA, Thurston G, Huang LE, et al. 2001. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1α. Genes Dev. 15:2520-32
42. Bruick RK, McKnight SL. 2002. Building better vasculature. Genes Dev. 15:2497-502
43. Li J, Post M, Volk R, et al. 2000. PR39, a peptide regulator of angiogenesis. Nat. Med. 6:49-55
44. Folkman J. 2000. Tumor angiogenesis. See Ref. 67, pp. 132-52
45. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-64
46. Zetter BR. 1998. Angiogenesis and tumor metastasis. Annu. Rev. Med. 49:407-24
47. Hockel M, Vaupel P. 2001. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93:266-76
48. Semenza GL. 2002. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8(Suppl.):S62-67
49. Birner P, Gatterbauer B, Oberhuber G, et al. 2001. Expression of hypoxia-inducible factor-1α in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92:165-71
50. Zagzag D, Zhong H, Scalzitti JM, et al. 2000. Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606-18
51. Birner P, Schindl M, Obermair A, et al. 2001. Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7:1661-68
52. Bos R, Zhong H, Hanrahan CF, et al. 2001. Levels of hypoxia-inducible factor 1α during breast carcinogenesis. J. Natl. Cancer Inst. 93:309-14
53. Liotta LA, Kohn EC. 2000. Invasion and metastasis. See Ref. 67, pp. 121-31
54. Birner P, Schindl M, Obermair A, et al. 2000. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 60:4693-96
55. Aebersold DM, Burri P, Beer KT, et al. 2001. Expression of hypoxia-inducible factor 1: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61:2911-16
56. Karkkainen MJ, Makinen T, Alitalo K. 2002. Lymphatic endothelium: a new frontier of metastasis research. Nat. Cell Biol. 4:E2-5
57. Volpert OV, Zaichuk T, Zhou W, et al. 2002. Inducer-stimulated Fas targets activated endothelium for destruction by antiangiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. 4:349-57
58. Boehm T, Folkman J, Browder T, et al. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:335-36
59. Rohan RM, Fernandez A, Udagawa T, et al. 2000. Genetic heterogeneity of angiogenesis in mice. FASEB J. 14:871-76
60. Yu JL, Rak JW, Coomber BL, et al. 2002. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295:1526-28
61. Rak J, Yu JL, Kerbel RS, et al. 2002. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res. 62:1931-34
62. Semenza GL. 2002. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 19:59-65
63. Kerbel RS, Viloria-Petit A, Klement G, et al. 2000. 'Accidental' anti-angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur. J. Cancer 36:1248-57
64. Viloria-Petit A, Crombet T, Jothy S, et al. 2001. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61: 5090-101
65. Klement G, Baruchel S, Rak J, et al. 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:R15-24
66. Kerbel RS, Yu J, Tran J, et al. 2001. Possible mechanisms of acquired resistance to antiangiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20:79-86
67. Bast RC Jr, Kufe DW, Pollock RE, et al., eds. 2000. Cancer Medicine. Hamilton, Canada: Decker. 5th ed.